Endometrioid carcinoma of the endometrium: Pathologic and molecular features

Seminars in Diagnostic Pathology

Volumn 27, Issue 4, 2010, Pages 226-240

  Azueta, Ainara ^a   Gatius, Sonia ^a   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Endometrial carcinoma; Endometrioid; Histologic grade; Molecular features; Myometrial invasion; Stage

Indexed keywords

BETA CATENIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADENOMYOMA; ARTICLE; BREAST METASTASIS; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL DEDIFFERENTIATION; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COLON CANCER; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MICROSCOPY; MIXED MULLERIAN TUMOR; MUCINOUS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 78650194056     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2010.09.001     Document Type: Article

References (92)

1. Bockman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10-17.
2. Tavasoli F.A., Devilee P. Pathology and Genetics of Tumours of the Breast and Female Organs: WHO Classification of Tumours 2003, International Agency for Research on Cancer, Lyon.
3. Clement Ph.B., Young R.H. Endometrioid carcinoma of the uterus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2002, 3:145-184.
4. Sherman M.E., Silverberg S.G. Advances in endometrial pathology. Clin Lab Med 1995, 15:517-543.
5. Sivridis E., Giatromanolaki A. The endometrial hyperplasias revisited. Virchows Arch 2008, 453:223-231.
6. Salm R. The incidence and significance of early carcinomas in endometrial polyps. J Pathol 1972, 108:47-53.
7. Jacques S.M., Qureshi F., Lawrence W.D. Surface epithelial changes in endometrial adenocarcinoma: diagnostic pitfalls in curettage specimens. Int J Gynecol Pathol 1995, 14. 191-178.
8. Kim K.R., Scully R.E. Peritoneal keratin granulomas with carcinomas of endometrium and ovary and atypical polypoid adenomyoma of endometrium. A clinicopathologycal analysis of 22 cases. Am J Surg Pathol 1990, 14:925-932.
9. Ambros R.A., Malfetano J.H. Villoglandular adenocarcinoma of the endometrium. Am J Surg Pathol 1998, 22:1379-1385.
10. Ambros R.A., Ballouk F., Malfetano J.H., et al. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol 1994, 18:569-575.
11. Tobon H., Watkins G.J. Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol 1985, 4:328-335.
12. Garg K., Soslow R.A. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 2009, 62:679-684.
13. Tafe L.J., Garg K., Chew I., et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010, 23:781-789.
14. Murray S.K., Young R.H., Scully R.E. Uterine endometrioid carcinoma with small nonvillous papillae: an analysis of 26 cases of a favourable-prognosis tumor to be distinguished from serous carcinoma. Int J Surg Pathol 2000, 8:279-289.
15. Young R.H., Scully R.E. Uterine carcinomas simulating microglandular hyperplasia: a report of six cases. Am J Surg Pathol 1992, 16:1092-1097.
16. Eichlom J.H., Young R.H., Clement P.B. Sertoliform endometrial adenocarcinoma: a study of four cases. Int J Gynecol Pathol 1996, 15:119-126.
17. Liang S.X., Patel K., Pearl M., et al. Endometrioid carcinoma of the endometrium with dual immunophenotypes for epithelial membrane antigen and inhibin alpha: case report and literature review. Int J Gynecol Pathol 2007, 26:291-297.
18. Murray S.K., Clement P.B., Young R.H. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol 2005, 29:157-166.
19. Mooney E.E., Robboy S.J., Hammond C.B., et al. Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis. Int J Gynecol Pathol 1997, 16:169-172.
20. Pesce C., Merino M.J., Chambers J.T., et al. Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer. Cancer 1991, 68:1799-1802.
21. Hoshida Y., Nagakawa T., Mano S., et al. Hepatoid adenocarcinoma of the endometrium associated with alpha-fetoprotein production. Int J Gynecol Pathol 1996, 15:266-269.
22. Toyoda H., Hirai T., Ishii E. Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium. Pathol Int 2000, 50:847-852.
23. Silva E.G., Young R.H. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol 2007, 31:1203-1208.
24. Melhem M.F., Tobon H. Mucinous adenocarcinoma of the endometrium: a clinicopathologycal review of 8 cases. Int J Gynecol Pathol 1987, 6:347-355.
25. Catasús Ll, Machin P., Matias-Guiu X., et al. Microsatellite instability in endometrial carcinomas clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998, 29:1160-1164.
26. Silva E.G., Deavers M.T., Bodurka D.C., et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?. Int J Gynecol Pathol 2006, 25:304.
27. Wheeler D.T., Bristow R.E., Kurman R.J. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007, 31:988-998.
28. Sheehan J.F., Schmitz H.E. Histologic changes produced by radiation in adenocarcinomas of the uterus; comparison with changes produced in squamous cell carcinomas of cervix. Am J Clin Pathol 1950, 20:241-252.
29. Staebler A., Sherman M.E., Zaino R.J., et al. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 2002, 26:998-1006.
30. Ansari-Lari M.A., Staebler A., Zaino R.J., et al. Distinction of endocervical and endometrial adenocarcinomas: Immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004, 28:160-167.
31. Tambouret R., Clement P.B., Young R.H. Endometrial endometrioid adenocarcinoma with a deceptive pattern of spread to the uterine cervix: a manifestation of stage IIb endometrial carcinoma liable to be misinterpreted as an independent carcinoma or a benign lesion. Am J Surg Pathol 2003, 27:1080-1088.
32. Kamoi S., AlJuboury M.I., Akin M.R., et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 2002, 21:217-223.
33. Castrillon D.H., Lee K.R., Nucci M.R. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 2002, 21:4-10.
34. McCluggage W.G., Sumathi V.P., McBride H.A., et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002, 21:11-15.
35. Alkushi A., Irving J., Hsu F., et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003, 442:271-277.
36. Hsu J.D., Yao C.C., Lee M.Y., et al. True cytokeratin immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol 2010, 29:282-289.
37. McCluggage W.G., Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003, 22:231-235.
38. Chew I, Post M, Carinelli SG, et al. p16 expression in tumors with squamous differentiation and trophoblastic lesions of the upper female genital tract. Int J Gynecol Pathol, in press.
39. Yemelyanova A., Ji H., Shih Ie.M., et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009, 33:1504-1514.
40. Yemelyanova A., Vang R., Seidman J.D., et al. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol 2009, 33:914-924.
41. Kong C.S., Beck A.H., Longacre T.A. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol 2010, 34:915-926.
42. Mazur M.T. Atypical polypoid adenomyomas of the endometrium. Am J Surg Pathol 1981, 5:473-482.
43. Longacre T.A., Chung M.H., Jensen D.N., et al. Proposed criteria for the diagnosis of well-differentiated endometrial carcinoma. A diagnostic test for myoinvasion. Am J Surg Pathol 1995, 19:371-406.
44. Ohishi Y., Kaku T., Kobayashi H., et al. CD10 immunostaining distinguishes atypical polypoid adenomyofibroma (atypical polypoid adenomyoma) from endometrial carcinoma invading the myometrium. Hum Pathol 2008, 39:1446-1453.
45. Longacre T.A., Chung M.H., Rouse R.V., et al. Atypical polypoid adenomyofibromas (atypical polypoid adenomyomas) of the uterus. A clinicopathologic study of 55 cases. Am J Surg Pathol 1996, 20:1-20.
46. Clarke B., Gilks B. Endometrial carcinoma: controversies in histopathologycal assessment of grade and tumour cell type. J Clin Pathol 2010, 63:410-415.
47. Schlosshauer P.W., Ellenson L.H., Soslow R.A. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histologycal subtype. Mod Pathol 2002, 15:1032-1037.
48. Mount S.L. Mucinous metaplasias of the endometrium: biologically meaningful subsets for the practicing surgical pathologist. Adv Anat Pathol 2000, 7:197-200.
49. Nucci M.R., Prasad C.J., Crum C.P., et al. Mucinous endometrial epithelial proliferations: a morphologic spectrum of changes with diverse clinical significance. Mod Pathol 1999, 12:1137-1142.
50. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004, 35:649-662.
51. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009, 105:103-104.
52. Zaino R.J., Kurgan R.J., Diana K.L., et al. The utility of the revised Internacional Federation of Gynecology and Obstetrics histologic grading system. A Gynecologic Oncology Group Study. Cancer 1995, 75:81-86.
53. Takeshima N., Hirai Y., Hasumi K. Prognostic validity of neoplastic cells with notable nuclear atypia in endometrial cancer. Obstet Gynecol 1998, 92:119-123.
54. Taylor R.R., Zeller J., Lieberman R.W., et al. An analysis of two versus three grades for endometrial. Gynecol Oncol 1999, 92:119-123.
55. Lax S.F., Kurgan R.J., Pizer E.S., et al. A binary architectural grading system for compared with FIGO grading and identifies subsets of advance-stage tumors with favourable and unfavourable prognosis. Am J Surg Pathol 2000, 24:1201-1208.
56. Scholten A.N., Smit V.T., Beerman H., et al. Prognostic significance and interobserver variability of histologic grading system for endometrial carcinoma. Cancer 2004, 100:764-772.
57. Alkushi A., Abdul-Rahman Z.H., Lim P., et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005, 29:295-304.
58. Kalvanasundaram K., Ganesan R., Perunovic B., et al. Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Gynecol Pathol 2010, 18:138-143.
59. Murray S.K., Young R.H., Scully R.E. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 2003, 22:324-333.
60. Ali A., Black D., Soslow R.A. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 2007, 26:115-123.
61. Mittal K.R., Barwick K.W. Endometrial adenocarcinoma involving adenomyosis without the myometrial invasion is characterized by frequent preceding estrogen therapy, low grade, and excellent prognosis. Gynecol Oncol 1993, 49:197-201.
62. Nascimiento A.F., Hirsch M.S., Cviko A., et al. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma involving adenomyiosis. Mod Pathol 2003, 16:22-27.
63. Koshiyama M., Suzuki A., Ozawa M., et al. Adenocarcinomas arising from uterine adenomyosis: a report of four cases. Int J Gynecol Pathol 2002, 21:239-245.
64. Alkushi A., Clarke B.A., Akbari M., et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007, 20:1156-1165.
65. Lax S.F., Kurman R.J. A dualistic model for endometrial carcinogenesis based on immmunohistoquemical and molecular genetic analyses. Verh Dtsch Ges Path 1997, 81:228-232.
66. Matías-Guiu X., Catasús L., Bussaglia E., et al. Molecular pathology of endometrial hyperplasia and carcinoma. Am J Pathol 1996, 148:1671-1678.
67. Moreno-Bueno G., Sánchez-Estévez C., Cassia R., et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003, 63:5697-5702.
68. Risinger J.I., Maxwell G.L., Chandramouli G.V., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003, 63:6-11.
69. Cao Q.J., Belbin T., Socci N., et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004, 23:321-329.
70. Risinger J.I., Maxwell G.L., Chandramouli G.V., et al. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. Cancer Res 2005, 65:5031-5037.
71. Caduff R.F., Johnston C.M., Svoboda-Newman S.M., et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996, 148:1671-1678.
72. Duggan B.D., Felix J.C., Muderspach L.I., et al. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994, 86:1216-1221.
73. Catasus Ll, Matias-Guiu X., Machin P., et al. BAX somatic framshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrioid carcinomas with microsatellite instability. Lab Invest 1998, 78:1439-1444.
74. Catasus Ll, Matias-Guiu X., Machin P., et al. Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinomas with microsatellite instability. Cancer 2000, 88:2290-2297.
75. Terakawa N., Kanamori Y., Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003, 10:203-208.
76. Salvesen H.B., Stefansson I., Kalvenes M.B., et al. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002, 94:2185-2191.
77. Bussaglia E., del Rio E., Matias-Guiu X., et al. PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000, 31:312-317.
78. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000, 92:924-931.
79. Podsypanina K., Lee R.T., Politis C., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/-mice. Proc Natl Acad Sci U S A 2001, 28:10320-10325.
80. Oda K., Stokoe D., Taketani Y., et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65:10669-10673.
81. Velasco A., Bussaglia E., Pallares J., et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 2006, 37:1465-1472.
82. Catasus L., Gallardo A., Cuatrecasas M., et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008, 21:131-139.
83. Dutt A., Salvesen H.B., Chen T.H., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008, 105:8713-8717.
84. Lagarda H., Catasus Ll, Argüelles R., et al. K-ras mutations in endometrial carcinoma with microsatellite instabilit. J Pathol 2001, 193:193-199.
85. Pallarés J., Velasco A., Eritja N., et al. Promoter hypermethylation and reduced expresión of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 2008, 21:661-699.
86. Fukuchi T., Sakamoto M., Tsuda H., et al. Beta-catenin mutations in carcinoma of the uterine endometrium. Cancer Res 1998, 58:3526-3528.
87. Kobayashi K., Sagae S., Nishioka Y., et al. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999, 90:55-59.
88. Machin P., Catasus L., Pons C., et al. 1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002, 33:206-212.
89. Pallares J., Martinez-Guitarte J.L., Dolcet X., et al. Abnormalities in NF-kB family and related proteins in endometrial carcinoma. A tissue microarray study. J Pathol 2004, 13:569-577.
90. Dolcet X., Llobet D., Pallares J., et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005, 85:885-894.
91. Pallarés J., Llobet D., Santacana M., et al. CK2B is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am J Pathol 2009, 174:287-296.
92. Planagumà J., Díaz-Fuertes M., Gil-Moreno A., et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res 2004, 64:8846-8853.